Effects of lapatinib monotherapy: Results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck

British Journal of Cancer

Volumn 105, Issue 5, 2011, Pages 618-627

  Del Campo, J M ^a   Hitt, R ^b   Sebastian, P ^c   Carracedo, C ^d   Lokanatha, D ^e   Bourhis, J ^f   Temam, S ^f   Cupissol, D ^g   De Raucourt, D ^h   Maroudias, N ⁱ   Nutting, C M ^j   Compton, N ^k   Midwinter, D ^k   Downie, L ^k   Biswas Baldwin, N ^k   El Hariry, I ^k   Harrington, K J ^j  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c REGIONAL CANCER CENTRE   (India)

^d INSTITUTO NACIONAL DE ENFERMEDADES NEOPLÁSICAS   (Peru)

^e KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY   (India)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g CENTRE VAL D AURELLE   (France)

^h CENTRE FRANÇOIS BACLESSE   (France)

ⁱ Appollonion Private Hospital   (Cyprus)

^j ROYAL MARSDEN HOSPITAL   (United Kingdom)

^k GLAXOSMITHKLINE   (United Kingdom)

more..

Author keywords

epidermal growth factor receptor; lapatinib; squamous cell carcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORODEOXYGLUCOSE; LAPATINIB;

ADULT; ADVANCED CANCER; AGED; APOPTOSIS; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; DYSPHAGIA; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY; ODYNOPHAGIA; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTINEOPLASTIC AGENTS; CARCINOMA; DISEASE PROGRESSION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASMS, SQUAMOUS CELL; PLACEBOS; QUINAZOLINES; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 80052029219     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.237     Document Type: Article

References (49)

1. Abidoye OO, Cohen EE, Wong SJ, Kozloff MF, Nattam SR, Stenson KM, Blair EA, Day S, Dancey JE, Vokes EE (2006) A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 24(suppl): 5568
2. Agulnik M, da Cunha Santos G, Hedley D, Nicklee T, Dos Reis PP, Ho J, Pond GR, Chen H, Chen S, Shyr Y, Winquist E, Soulieres D, Chen EX, Squire JA, Marrano P, Kamel-Reid S, Dancey J, Siu LL, Tsao MS (2007) Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J Clin Oncol 25(16): 2184-2190 (Pubitemid 46954641)
3. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK, Milas L (2002) Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62(24): 7350-7356 (Pubitemid 36025259)
4. Banerji U, de Bono J, Judson I, Kaye S, Workman P (2008) Biomarkers in early clinical trials: the committed and the skeptics. Clin Cancer Res 14(8): 2512-2514
5. Bartelink H, Begg A, Martin JC, van Dijk M, van 't Veer L, van der Vaart P, Verheij M (1999) Towards prediction and modulation of treatment response. Radiother Oncol 50(1): 1-11 (Pubitemid 29136732)
6. Bonner JA, De Los Santos J, Waksal HW, Needle MN, Trummel HQ, Raisch KP (2002) Epidermal growth factor receptor as a therapeutic target in head and neck cancer. Semin Radiat Oncol 12(3 Supplement 2): 11-20 (Pubitemid 34920087)
7. Burstein HJ, Storniolo AM, Franco S, Forster J, Stein S, Rubin S, Salazar VM, Blackwell KL (2008) A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol 19(6): 1068-1074 (Pubitemid 351796331)
8. Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, Chan S, Jagiello-Gruszfeld A, Kaufman B, Crown J, Chan A, Campone M, Viens P, Davidson N, Gorbounova V, Raats JI, Skarlos D, Newstat B, Roychowdhury D, Paoletti P, Oliva C, Rubin S, Stein S, Geyer CE (2008) A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 112(3): 533-543
9. Cancer Therapy Evaluation Program. (2006) Common Terminology Criteria for Adverse Events, v3.0. National Cancer Institute, http://ctep.cancer.gov/ protocolDevelopment/electronic-applications/docs/ctcaev3.pdf. Published 9 August 2006. Accessed 4 January 2010.
10. Chu I, Blackwell K, Chen S, Slingerland J (2005) The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation-and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res 65(1): 18-25 (Pubitemid 40070791)
11. Chung CH, Ely K, McGavran L, Varella-Garcia M, Parker J, Parker N, Jarrett C, Carter J, Murphy BA, Netterville J, Burkey BB, Sinard R, Cmelak A, Levy S, Yarbrough WG, Slebos RJ, Hirsch FR (2006) Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 24(25): 4170-4176 (Pubitemid 46622295)
12. Cohen EE, Lingen MW, Martin LE, Harris PL, Brannigan BW, Haserlat SM, Okimoto RA, Sgroi DC, Dahiya S, Muir B, Clark JR, Rocco JW, Vokes EE, Haber DA, Bell DW (2005) Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res 11(22): 8105-8108 (Pubitemid 41698754)
13. Coley HM, Shotton CF, Ajose-Adeogun A, Modjtahedi H, Thomas H (2006) Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitis-ing EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents. Biochem Pharmacol 72(8): 941-948 (Pubitemid 44376781)
14. Collins JA, Schandi CA, Young KK, Vesely J, Willingham MC (1997) Major DNA fragmentation is a late event in apoptosis. J Histochem Cytochem 45(7): 923-934 (Pubitemid 27284016)
15. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman A, Machtay M, Ensley JF, Chao KS, Schultz CJ, Lee N, Fu KK, Radiation Therapy Oncology Group 9501/Intergroup (2004) Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. New Engl J Med 350(19): 1937-1944
16. Doroshow JH, Parchment RE (2008) Oncologic phase 0 trials incorporating clinical pharmacodynamics: from concept to patient. Clin Cancer Res 14(12): 3658-3663
17. Eriksen JG, Steiniche T, Askaa J, Alsner J, Overgaard J (2004) The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys 58(2): 561-566 (Pubitemid 38142484)
18. Erjala K, Sundvall M, Junttila TT, Zhang N, Savisalo M, Mali P, Kulmala J, Pulkkinen J, Grenman R, Elenius K (2006) Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res 12(13): 4103-4111 (Pubitemid 44078099)
19. Ginsberg D (2007) EGFR signaling inhibits E2F1-induced apoptosis in vivo: implications for cancer therapy. Sci STKE 2007 (371): pe4
20. Goel S, Hidalgo M, Perez-Soler R (2007) EGFR inhibitor-mediated apoptosis in solid tumors. J Exp Ther Oncol 6(4): 305-320 (Pubitemid 350104820)
21. Goulart BH, Clark JW, Pien HH, Roberts TG, Finkelstein SN, Chabner BA (2007) Trends in the use and role of biomarkers in phase I oncology trials. Clin Cancer Res 13(22 Part 1): 6719-6726 (Pubitemid 350206809)
22. Gown AM, Willingham MC (2002) Improved detection of apoptotic cells in archival paraffin sections: immunohistochemistry using antibodies to cleaved caspase 3. J Histochem Cytochem 50(4): 449-454 (Pubitemid 34250583)
23. Grabenbauer G, Suckorada O, Niedobitek G, Rödel F, Iro H, Sauer R, Rödel C, Schultze-Mosgau S, Distel L (2003) Imbalance between proliferation and apoptosis may be responsible for treatment failure after postoperative radiotherapy in squamous cell carcinoma of the oropharynx. Oral Oncol 39(5): 459-469 (Pubitemid 36579113)
24. Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, Endo S, Johnson DE, Huang L, He Y, Kim JD (2000) Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci USA 97(8): 4227-4232 (Pubitemid 30226115)
25. Grandis JR, Tweardy DJ (1993) Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 53(15): 3579-3584 (Pubitemid 23229640)
26. Harari PM, Allen GW, Bonner JA (2007) Biology of interactions: antiepidermal growth factor receptor agents. J Clin Oncol 25(26): 4057-4065 (Pubitemid 47492950)
27. Harrington K, Jankowska P, Hingorani M (2007) Molecular biology for the radiation oncologist: the 5Rs of radiobiology meet the hallmarks of cancer. Clin Oncol 19(8): 561-571 (Pubitemid 47308644)
28. Harrington KJ, Berrier A, Robinson M, Remenar E, Housset M, Hurtado de Mendoza F, Compton N, Lau M, Legenne P, Kumar R (2010) Phase II study of oral lapatinib, a dual-tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 28(Suppl): 15s (abstract 5505)
29. Harrington KJ, El-Hariry IA, Holford CS, Lusinchi A, Nutting CM, Rosine D, Tanay M, Deutsch E, Matthews J, D'Ambrosio C, Turner SJ, Pandeshwara JS, Bourhis J (2009) Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 27(7): 1100-1107
30. Hitt R, Ciruelos E, Amador ML, Benito A, Sanchez JJ, Ballestin C, Cortes-Funes H (2005) Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy. Eur J Cancer 41(3): 453-460 (Pubitemid 40187218)
31. Hotz MA, Bosq J, Zbaeren P, Reed J, Schwab G, Krajewski S, Brousset P, Borner MM (1999) Spontaneous apoptosis and the expression of p53 and Bcl-2 family proteins in locally advanced head and neck cancer. Arch Otolaryngol Head Neck Surg 125(4): 417-422 (Pubitemid 29169768)
32. Johns TG, Luwor RB, Murone C, Walker F, Weinstock J, Vitali AA, Perera RM, Jungbluth AA, Stockert E, Old LJ, Nice EC, Burgess AW, Scott AM (2003) Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478. Proc Natl Acad Sci USA 100(26): 15871-15876 (Pubitemid 38021082)
33. Kalyankrishna S, Grandis JR (2006) Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 24(17): 2666-2672 (Pubitemid 46622088)
34. Kaufmann SH, Vaux DL (2003) Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene 22(47): 7414-7430 (Pubitemid 37487167)
35. Konecny GE, Venkatesan N, Yang G, Dering J, Ginther C, Finn R, Rahmeh M, Fejzo MS, Toft D, Jiang SW, Slamon DJ, Podratz KC (2008) Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. Br J Cancer 98(6): 1076-1084 (Pubitemid 351399811)
36. Modjtahedi H, Affleck K, Stubberfield C, Dean C (1998) EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5. Int J Oncol 13(2): 335-342 (Pubitemid 28329223)
37. Potten CS (1996) What is an apoptotic index measuring? A commentary. Br J Cancer 74(11): 1743-1748 (Pubitemid 26401893)
38. El-Hariry I (2008) Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial. J Clin Oncol 26(14): 2285-2291
39. Rusnak DW, Alligood KJ, Mullin RJ, Spehar GM, Arenas-Elliott C, Martin AM, Degenhardt Y, Rudolph SK, Haws Jr TF, Hudson-Curtis BL, Gilmer TM (2007) Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines. Cell Prolif 40(4): 580-594 (Pubitemid 47063294)
40. Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, Keith BR, Murray DM, Knight WB, Mullin RJ, Gilmer TM (2001) The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 1(2): 85-94
41. Sarker D, Workman P (2007) Pharmacodynamic biomarkers for molecular cancer therapeutics. Adv Cancer Res 96: 213-268
42. Sheridan MT, Cooper RA, West CM (1999) A high ratio of apoptosis to proliferation correlates with improved survival after radiotherapy for cervical adenocarcinoma. Int J Radiat Oncol Biol Phys 44(3): 507-512 (Pubitemid 29258423)
43. Spector NL, Xia W, Burris III H, Hurwitz H, Dees EC, Dowlati A, O'Neil B, Overmoyer B, Marcom PK, Blackwell KL, Smith DA, Koch KM, Stead A, Mangum S, Ellis MJ, Liu L, Man AK, Bremer TM, Harris J, Bacus S (2005) Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 23(11): 2502-2512 (Pubitemid 47050840)
44. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3): 205-216 (Pubitemid 30099779)
45. Thomas F, Rochaix P, Benlyazid A, Sarini J, Rives M, Lefebvre JL, Allal BC, Courbon F, Chatelut E, Delord JP (2007) Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma. Clin Cancer Res 13(23): 7086-7092 (Pubitemid 350276892)
46. Tsuchiya K, Shirato H, Nishioka T, Yamazaki A, Hashimoto S, Kagei K, Oomori K, Yasuda M, Shindo M, Miyasaka K (2001) Pretreatment apoptotic scores do not predict response to radiation therapy in oropharyngeal squamous cell carcinoma. Oral Oncol 37(2): 159-163 (Pubitemid 32146662)
47. Willingham MC (1999) Cytochemical methods for the detection of apoptosis. J Histochem Cytochem 47(9): 1101-1110
48. Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, Owens G, Alligood KJ, Spector NL (2002) Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21(41): 6255-6263
49. Zhou Y, Li S, Hu YP, Wang J, Hauser J, Conway AN, Vinci MA, Humphrey L, Zborowska E, Willson JK, Brattain MG (2006) Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. Cancer Res 66(1): 404-411 (Pubitemid 43166048)